Related Articles

Alternative Medicine

Anti-inflammatory patch resolves swelling

FREDERICK, Md., July 7 /PRNewswire-FirstCall/

 

Last Updated:

ActiPatch(TM), the product marketed by Bioelectronics Corp. (Pink Sheets: BIEL), is changing the face of medicine and the way we heal. Recently chosen as "One of 9 Medical Breakthroughs That May Change Your Life," by MedicalHeadway.com, ActiPatch is fast becoming the treatment of choice for everything from soft tissue injuries to surgical recovery.

"The decision to include ActiPatch in the top 9 medical breakthroughs was an easy one," said Reginald Saxton, President of Medical Headway. "ActiPatch fills the void created by consumers who would rather not take pain medications and are seeking safe and effective alternative treatment options," Saxton added, "I knew our readers would be very interested in this product for that reason".

ActiPatch is a drug-free wafer thin patch with an embedded battery operated microchip that delivers weeks of continuous pulsed RF therapy for less than a dollar a day. The unique ActiPatch delivery system, using patented technology, provides a cost-effective, home use method that reduces soft tissue pain and swelling, and accelerates healing.
When using ActiPatch, bruises that would normally take three weeks to heal often heal in a week; ankle sprains usually respond positively with reduced pain and swelling in only a single day; plastic surgery incisions that would normally take weeks to heal typically heal in less than a week. These claims are supported by multiple clinical trials and strong endorsements from leading surgeons and physicians.

BioElectronics has already received FDA clearance for one surgical procedure, (blepharoplasty), and is now able to sell the product within the United States through physician referral. In addition, BioElectronics has received blanket approval in the European Union, Canada, and dozens of countries. These international approvals have allowed the product to be placed in stores for over-the-counter purchase outside the United States.

Andrew J. Whelan, CEO of BioElectronics Corporation, explains, "ActiPatch with its non-invasive, very efficient treatment for swelling and pain while accelerating recovery is the medicine of the future available today. We are actively pursuing additional reimbursement approvals nationally. ActiPatch is an important product that not only works without side-effects, it also has the potential to help keep medical costs down at a time when they appear to be spiraling out of control," adds Whelan.

This bruise is healing less than 24 hours after injury. You can clearly see where the ActiPatch was applied.

 

BioElectronics has taken proven medical technologies and made them available to more people in new convenient, cost-effective, anti-inflammatory patches. By applying advanced microelectronic technology, BioElectronics has dramatically reduced the size and the cost of some well-established medical treatments.

BioElectronics is the developer and marketer of ActiPatch™ medical devices which deliver pulsed electromagnetic frequency (PEMF) therapies to accelerate healing of soft tissue injuries. A reduction of pain and swelling allows patients to return to normal activities much sooner. This patented technology is based on clinically proven, widely accepted PEMF therapy.

The Company's ActiPatch is a drug-free, painless, pulsed energy patch. The ActiPatch has FDA clearance for the treatment of edema following blepharoplasty.

ActiPatch is:

• Is drug-free
• Reduces swelling and inflammation
• Lasts 10 to 30 days, depending on model
• Is comfortable
• Provides continuous treatment
• Is easy to use
• Is safe
• Is affordable
• Provides localized, non-systemic treatment
• Is lightweight

ActiPatch is not:

• Not A Magnet - ActiPatch delivers a pulsed electromagnetic field.
• Not Heat Therapy - ActiPatch is heat free, not a diathermy unit.
• Not A TENS Unit - Unlike TENS, PEMF does not deliver an electrical current through the body to block pain.
• Not A Pharmaceutical - ActiPatch in not ingested or injected and is not systemic.
• Not An Office Based Therapy - ActiPatch can be worn in the comfort of the patient's home.
• Not A Bone Growth Stimulator - ActiPatch delivers a low power pulse and is not designed to heal hard tissue (bone).
• BioElectronics Assets: The Company is a public company with significant accomplishments:
• FDA market clearance for the treatment of edema
• International Standards Organization (ISO) and CE (Conformité Européenne, French for European conformity) Certifications
• Health Canada Market clearance for the relief of musculoskeletal pain
• Strong intellectual property

The clinical effectiveness of the product has been well established. Testing performed at the Bioelectromagnetics Research Laboratory at the State University of New York has shown that ActiPatch Therapy provides an adequate dosage of electromagnetic energy for the treatment of soft tissue, and that its power at the skin level is equivalent to that of traditional high-power devices. The power level is six to nine orders of magnitude higher than that which is required to show a biological effect. It also demonstrated that the cumulative effect of continuous delivery provides greater therapeutic benefit than sporadic treatments. For more information on the testing and clinical effectiveness of this product.

Clinical Trials

In 2006, the Company and the Lahey Clinic jointly announced a three-year program to study the effects of ActiPatch Therapy on a variety of soft tissue injuries and related medical conditions. The internationally renowned Lahey Clinic of Boston, whose faculty is affiliated with the Medical Schools of Harvard and Tufts, has committed to initiating a number of double-blind clinical studies on ActiPatch Therapy in the areas of plastic surgery, orthopedics and chronic wound care. Results from these clinical trials will be submitted to the United States Food and Drug Administration (the FDA) for expanded indications for the use of ActiPatch Therapy.

The company also commenced a series of double-blind clinical trials to be conducted in conjunction with leading schools of podiatry and selected clinics to document the effects of ActiPatch on treating plantar fasciitis [heel pain]. The studies in started in March 2006. The Principal Investigator for the study is Dr. William Van der Reis, a Board Certified Orthopedic Surgeon and sports medicine specialist. The study protocol was approved by the Investigational Review Board, Coast IRB, of San Clemente, CA.

MedicalHeadway.com is an online medical breakthrough library published by Medical Headway, LLC of Houston, TX. Dedicated to arming the public with news of the latest breakthroughs in the world of medicine, the company offers consumers free and complete access to its growing library of cutting-edge, professional medical treatment and product information. "In our opinion, ActiPatch is a huge advance for millions of people who would rather not take a pill or who need faster pain relief ... a clear breakthrough everyone should know about," explains Saxton.
For more information visit http://www.bioelectronicscorp.com or call 866-757-2284.